Source:http://linkedlifedata.com/resource/pubmed/id/21233857
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2011-4-18
|
| pubmed:abstractText |
Immunotherapy is a promising approach for the treatment of cancers. Modified adenovirus 5 (Ad5) vectors have been used as a platform to deliver genes encoding tumor associated antigens (TAA). A major obstacle to Ad5 vector immunotherapy has been the induction of vector immunity following administration or the presence of pre-existing Ad5 immunity, which results in vector mitigation. It has been reported by us that the Ad5[E1-, E2b-] platform with unique deletions in the E1, E2b and E3 regions can induce potent cell mediated immunity (CMI) against delivered transgene products in the presence of pre-existing Ad5 immunity. Here we report the use of an Ad5[E1-, E2b-] vector platform expressing the TAA HER2/neu as a breast cancer immunotherapeutic agent. Ad5[E1-, E2b-]-HER2/neu induced potent CMI against HER2/neu in Ad5 naïve and Ad5 immune mice. Humoral responses were also induced and antibodies could lyse HER2/neu expressing tumor cells in the presence of complement in vitro. Ad5[E1-, E2b-]-HER2/neu prevented establishment of HER2/neu-expressing tumors and significantly inhibited progression of established tumors in Ad5 naïve and Ad5 immune murine models. These data demonstrate that in vivo delivery of Ad5[E1-, E2b-]-HER2/neu can induce anti-TAA immunity and inhibit progression of HER2/neu expressing cancers.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1476-5500
|
| pubmed:author | |
| pubmed:copyrightInfo |
© 2011 Nature America, Inc.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
326-35
|
| pubmed:dateRevised |
2011-11-1
|
| pubmed:meshHeading |
pubmed-meshheading:21233857-Adenoviridae,
pubmed-meshheading:21233857-Animals,
pubmed-meshheading:21233857-Antibodies, Neoplasm,
pubmed-meshheading:21233857-Antigens, Neoplasm,
pubmed-meshheading:21233857-Blotting, Western,
pubmed-meshheading:21233857-Breast Neoplasms,
pubmed-meshheading:21233857-Cell Line, Tumor,
pubmed-meshheading:21233857-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:21233857-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:21233857-Enzyme-Linked Immunospot Assay,
pubmed-meshheading:21233857-Female,
pubmed-meshheading:21233857-Genetic Vectors,
pubmed-meshheading:21233857-Immunotherapy,
pubmed-meshheading:21233857-Mice,
pubmed-meshheading:21233857-Mice, Inbred BALB C,
pubmed-meshheading:21233857-Neutralization Tests,
pubmed-meshheading:21233857-Receptor, erbB-2,
pubmed-meshheading:21233857-Specific Pathogen-Free Organisms,
pubmed-meshheading:21233857-Transgenes
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
|
| pubmed:affiliation |
Etubics Corporation, Seattle, WA 98119, USA. beth@etubics.com
|
| pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|